Trial Profile
Pharmacokinetic study of busulfan in allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies using once daily intravenous busulfan and fludarabine as conditioning regimen
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2018
Price :
$35
*
At a glance
- Drugs Busulfan (Primary) ; Fludarabine (Primary)
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
- Focus Pharmacokinetics
- Acronyms IVBU1002(FB4)-PK
- 31 Oct 2018 Status changed from recruiting to completed.
- 31 Jan 2013 New trial record